13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Technology

TEMPUS AI INC TEM

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.

Sources StockAnalysis company profile stockanalysis.com
Computer Software: Programming Data Processing

Company profile

Business mix

  • It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data.
  • The company also provides Lens, a software application for life sciences and advanced precision research.
  • In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions.
  • Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within health information services?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF -2.55% Buyback -20.28%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baillie Gifford legacy James Anderson 0.4% $391.1M 2026-03-31
Baron Capital Ron Baron 0.1% $40.7M 2026-03-31

Recent trading changes over the last 1 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 1 13F filing periods
Net reducers 2 Last 1 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $24.6M Estimated from net added shares
Reduction amount $49.3M Estimated from net reduced shares
Net share change / base shares -4.8% -483,816 / 10,032,450
Baron Capital Ron Baron 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 153.0% 13F value change +$19.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 355,446 Last 1 periods +543,832 (+153.0%) Total shares 899,278 Value $40.7M
Baillie Gifford legacy James Anderson 1 filing periods
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -1.1% 13F value change -$125.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 8,741,442 Last 1 periods -92,086 (-1.1%) Total shares 8,649,356 Value $391.1M
Coatue Management Philippe Laffont 1 filing periods
13F 2025-06-30 Filed 2025-08-14
Sold out Shares -100.0% 13F value change -$45.1M
Settlement As of 13F 2025-06-30 · Filed 2025-08-14
Base shares 935,562 Last 1 periods -935,562 (-100.0%) Total shares 0 Value $0

Recent mentions

No public mentions.